Pure Hyaluronic Acid      

BRA gives go-ahead for three projects

Date: 9th December 2008, Source: Althealth News

The Boston Redevelopment Authority approved projects that could add nearly 400 residences in the city, including an expansion in Charles River Park. The BRA gave the green light to developer Equity Residential to move forward with the West End Residences at Emerson Place. The residences plan 306 rental apartments, 15 percent of which will be affordable. Equity said the project will be the first residential development in the West End in 20 years. At 131 Green St. in Jamaica Plain, the BRA approved a ''transit-oriented development project" with 21 town house condos near the MBTA Green Street station. Another project that got BRA approval was one with 29 town houses at 131 Brookley Road in the same neighborhood. (Chris Reidy)

ADVERTISEMENT

Hub company loses ruling in Germany

A German court has ruled that Energizer Holdings Inc.'s four-bladed Quattro razor does not infringe on Gillette Co.'s European patent on a three-bladed design, Energizer said. In the latest development in a feud between the world's largest makers of wet-shave products, the court also ordered Gillette, the market leader, to reimburse Energizer's unspecified court costs. The ruling came 11 months after a federal judge in Massachusetts issued a similar finding, denying Boston-based Gillette's request for a preliminary injunction in the United States. Gillette spokesman Eric Kraus said the company would appeal, adding, ''We have been consistent in our rigorous defense of our intellectual property and we do not intend to abandon the claim based on this ruling." (AP)

Gaiety Theatre owner seeks demolition

The owner of the defunct Gaiety Theatre has asked the City of Boston for a demolition permit, but a group of preservationists wants to save the nearly 100-year-old building. Kensington Investment Co. wants to tear down the structure and put up an apartment building nearly 300 feet tall. Kensington already has its major approvals from the Boston Redevelopment Authority for the project, at the corner of Washington and LaGrange streets near Chinatown. (Chris Reidy)

Genzyme, partner get OK for wrinkle gel

Inamed Corp. and its partner Genzyme Corp. won US approval to sell the Captique wrinkle gel, a dermal filler product based on Genzyme's nonanimal stabilized hyaluronic acid technology. The treatment is Inamed's first wrinkle filler that is not derived from animals. The Food and Drug Administration cleared Captique to correct moderate to severe facial wrinkles, Inamed said. Genzyme and Inamed disclosed the clearance after US markets closed. (Bloomberg)

Inverness Medical to restate earnings

Inverness Medical Innovations Inc. will restate earnings downward for all previous periods through 2002 because of an error in calculating deferred taxes. Waltham-based Inverness, which restated 2002 earnings this year following a Securities and Exchange Commission review of an intercompany loan, also cut its earnings outlook for 2005 by 12 cents a share, citing the error. The diagnostics company said restatements will widen its 2002 loss of $4.63 a share by 8 cents, and decrease 2003 earnings of 64 cents a share by 10 cents. The adjustments will widen the loss in each of the first two quarters of 2004 by 4 cents a share, and by 3 cents in the third quarter. (Dow Jones)